EGFR Mutation Clinical Trials in Wuhan, Hubei
2 recruitingWuhan, Hubei, China
Showing 1–2 of 2 trials
Recruiting
Phase 1Phase 2
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
HER2 MutationAdvanced Non-Small Cell Lung CancerEGFR Mutation
Bayer400 enrolled94 locationsNCT05099172
Recruiting
Phase 2
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
Non-Small Cell Lung Cancer With EGFR Mutation
Abbisko Therapeutics Co, Ltd54 enrolled5 locationsNCT06668103